| Transport Package: | Carton |
|---|---|
| Specification: | 0.5g |
| Trademark: | Focus |
| Origin: | China |
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier
| Product name | Montelukast sodium particles |
| Main Ingredients | Montelukast |
| Adaptation disease | The product is indicated for the prophylaxis and long-term treatment of asthma in children over 1 years of age, including the prevention of daytime and nighttime asthma symptoms, the treatment of asthmatic patients who are sensitive to aspirin, and the prevention of exercise-induced bronchoconstriction. This product is intended to relieve the symptoms caused by allergic rhinitis (seasonal and perennial allergic rhinitis in children aged 2 to 5 years). |
| Dosage form | Granule |
| Character | This product is white granule |
| Specification | 0.5g(Montelukast 4 mg) |
| Usage and dosage | Once a day. Asthma patients should take it before bed. Allergic rhinitis patients can take medicine as long as necessary according to their condition. Patients with both asthma and allergic rhinitis should take the medicine once a night. Patients with both asthma and allergic rhinitis should take the medicine once a night. Children 1 to 2 years old with asthma, once a day, one bag at a time. Children 2 to 5 years of age with asthma and/or 2 to 5 years of age with allergic rhinitis should take 4 mg oral granulose-bag daily. |
| Storage | Keep away from light, sealed, in a cool (not more than 20 ºC) dry place |
| Origin | China |
| validity | 24 months |
| Tatoo | Allergic to any of the ingredients in this product is not allowed. |
| Notice | 1. The efficacy of oral administration in the treatment of acute asthma attacks has not been determined. Therefore, it should not be used to treat acute asthma attacks. Patients should be informed to prepare appropriate salvage medications. Sudden substitution of inhaled or oral glucocorticoids should not be used, although the combined dose of inhaled corticosteroids may be gradually reduced under the guidance of a physician. Neuropsychiatric events have been reported in patients taking this product (see adverse reactions). As other factors may also cause these events, they cannot be confirmed to be related to this product. Physicians should discuss these adverse events with patients and/or caregivers. The patient and/or caregiver should be informed and the doctor should be notified if these conditions occur. Patients treated with antiasthmatic medications, including leukotriene receptor antagonists, rarely develop one or more of the following conditions: acidic granulocytosis, vascular rash, worsening of pulmonary symptoms, cardiac complications, and/or neuropathy (sometimes diagnosed as churg-Strauss syndrome, a systemic eosinophilic vasculitis). These conditions are sometimes associated with reduction or discontinuation of oral glucocorticoid therapy. Although the causal relationship between these conditions and leukotriene receptor antagonists has not been established, attention and appropriate clinical monitoring are recommended for patients taking singulair. 2. Medication for pregnant and lactating women Pregnant women should avoid taking this product unless explicitly required. Global post-marketing experience has shown that rare neonatal congenital limb defects have been reported after use of this product during pregnancy. The vast majority of these women also used other asthma medications during pregnancy. A causal relationship between the use of this product and these events has not been established. It is not clear whether this product can be secreted from breast milk. Since many drugs can be secreted from breast milk, lactating women should use this product with caution. 3. Medication for children Safety and efficacy studies have been conducted in children aged 6 months to 14 years. For children aged 2 to 14 years, please refer to montelukast sodium chewable tablets [Usage and dosage]. Safety and efficacy in children younger than 6 months have not been studied. Studies have shown that this product does not affect the growth rate of children. Special patient 4. There is no need to adjust the dose for the elderly, patients with renal insufficiency or patients with mild to moderate hepatic insufficiency. There was no clinical data for montelukast in patients with severe liver insufficiency (Child-pugh score >9). |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}